Close Menu

NEW YORK (GenomeWeb) – Diagnostics manufacturer Quidel reported after the close of the market on Wednesday that its fourth quarter revenues rose 15 percent year over year, due primarily to growth in its rapid immunoassay business.

"Q4 was really good, 2019 was fine [and] in line with expectations, and we're really looking forward to 2020 on a number of fronts," said Quidel CEO Doug Bryant on a call with analysts and investors to recap the results. "Camaraderie in this company is terrific, and the morale and happiness of our employees has never been higher," he added.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.